TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
TGTXNEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year.
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
TGTX(NASDAQ:TGTX) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share.
TG Therapeutics Presents Data Highlighting BRIUMVI In Patients With Relapsing Forms Of Multiple Sclerosis, At 2025 CMSC Annual Meeting
TGTXTG Therapeutics Announces Upcoming Schedule Of Presentations Highlighting BRIUMVI Data In Patients With RMS, At 2025 CMSC Annual Meeting
TGTXTG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
TGTXTG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.
TG Therapeutics Q1 EPS $0.03 Misses $0.17 Estimate, Sales $120.86M Beat $118.43M Estimate
TGTXPrice Over Earnings Overview: TG Therapeutics
TGTXStock Of The Day: TG Therapeutics Breaks Out, May Head Higher
TGTXTG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher.
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target
TGTXTG Therapeutics Expects Full Year 2025 Revenue Of Approximately $540M Versus Consensus Of $548.20M, Including Briumvi U.S. Net Product Revenue Of Approximately $525M
TGTXTG Therapeutics Q4 2024 GAAP EPS $0.15, Inline, Sales $108.19M Beat $99.95M Estimate
TGTXExpert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts
TGTXHC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target
TGTXWhat's Going On With TG Therapeutics Stock Tuesday?
TGTXTG Therapeutics Inc (NASDAQ:TGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024.
TG Therapeutics Expects Q4 BRIUMVI US Net Product Revenue Of $103.6M, FY24 RIUMVI US Net Product Revenue Of $310M, FY25 Total Revenue Of $540M
TGTXHC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $55
TGTXGoldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $22
TGTXFUJIFILM Diosynth Biotechnologies Announces That TG Therapeutics Has Committed To A Multi-Year Manufacturing Supply Agreement For BRIUMVI, Its U.S. FDA-Approved Therapeutic For Relapsing Forms Of Multiple Sclerosis
TGTXTG Therapeutics Says It Is On Path For Continued Growth Into End Of The Year And Into 2025 And Further Toward Long-term
TGTXTG Therapeutics Raising FY24 BRIUMVI US Net Product Revenue Target To $300M - $305M From Prior Guidance Of $290M - $300M
TGTXTG Therapeutics Q3 2024 GAAP EPS $0.02, Inline, Sales $83.88M Beat $81.71M Estimate
TGTXTG Therapeutics Shares Spike to Highs; May $10 Calls Active
TGTX